Health Technology Assessment (HTA) Consumer Consultative Committee (CCC)

HTA CCC Communique – 10 and 11 September 2025 30th Meeting of the HTA CCC

Attendees

Consumer representatives from the Pharmaceutical Benefits Advisory Committee (PBAC) and its subcommittees, the Medical Services Advisory Committee (MSAC) and its subcommittees, the Life Saving Drugs Program (LSDP) Expert Panel, the Medicare Benefits Schedule Review Advisory Committee (MRAC) and the Medical Devices and Human Tissue Advisory Committee (MDHTAC).

Departmental representatives from the Consumer Evidence and Engagement Unit (CEEU) and the Office of Health Technology Assessment (OHTA).

Outcomes

The Chair of the <u>HTA Review Implementation Advisory Group</u> (IAG), Professor Andrew Wilson, was welcomed and presented to the HTA CCC on the IAG work to date and the draft Implementation Roadmap.

The Assistant Secretary of the Australia's Disability Strategy Branch in the recently established Disability and Carers Group within the Department of Health, Disability and Ageing provided an overview of the disability sector. HTA CCC members discussed considerations of people living with a disability within HTA processes.

The HTA CCC was provided a presentation on patient evidence in HTA and participated in a workshop to consider how relevant evidence may be gathered and integrated into the broader health technology assessment process. The HTA CCC continued discussions on the further development of HTA committees' consumer engagement processes, including ways to improve communication mechanisms and approaches.

Focus areas for future work of the HTA CCC were proposed by the Chair for members' consideration and input. The various items discussed during the meeting informed these potential work themes, which will be further developed into a 2-year HTA CCC Work Plan.

The next HTA CCC meeting is scheduled to be held in February 2026.